Literature DB >> 33428600

Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway.

Tang Hexiao1, Bai Yuquan1, Xiong Lecai1, Wei Yanhong2, Shen Li3, Hu Weidong1, Xu Ming1, Zhou Xuefeng1, Pan Gaofeng1, Zhang Li1, Zhu Minglin1, Tang Zheng1, Yang Zetian1, Zhou Xiao1, Cai Yi1, Michael Lanuti3, Zhao Jinping1.   

Abstract

Many studies have reported that estrogen (E2) promotes lung cancer by binding to nuclear estrogen receptors (ER), and altering ER related nuclear protein expressions. With the GEO database analysis, Human centromere protein F (CENPF) is highly expressed in lung adenocarcinoma (LUAD), and the co-expression of CENPF and ERβ was found in the nucleus of LUAD cells through immunofluorescence. We identified the nuclear protein CENPF and explored its relationship with the ER pathway. CENPF and ERβ2/5 were related with T stage and poor prognosis (P<0.05). CENPF knockout significantly inhibited LUAD cell growth, the tumor growth of mice and the expression of ERβ2/5 (P<0.05). The protein expression of CENPF and ERβ2/5 in the CENPF-Knockdown+Fulvestrant group was lower than CENPF- Negative Control +Fulvestrant group (P=0.002, 0.004, 0.001) in A549 cells. The tumor size and weight of the CENPF-Knockdown+Fulvestrant group were significantly lower than CENPF- Negative Control +Fulvestrant group (P=0.001, 0.039) in nude mice. All the results indicated that both CENPF and ERβ2/5 play important roles in the progression of LUAD, and knockdown CENPF can inhibit the progression of LUAD by inhibiting the expression of ER2/5. Thus, the development of inhibitors against ERβ2/5 and CENPF remained more effective in improving the therapeutic effect of LUAD.

Entities:  

Keywords:  WGCNA package; centromere protein F (CENPF); estrogen receptor beta; lung adenocarcinoma (LUAD); non-small cell lung cancer (NSCLC)

Mesh:

Substances:

Year:  2021        PMID: 33428600      PMCID: PMC7880349          DOI: 10.18632/aging.202303

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  36 in total

1.  Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.

Authors:  Gee-Chen Chang; Chien-Hua Tseng; Kuo-Hsuan Hsu; Chong-Jen Yu; Cheng-Ta Yang; Kun-Chieh Chen; Tsung-Ying Yang; Jeng-Sen Tseng; Chien-Ying Liu; Wei-Yu Liao; Te-Chun Hsia; Chih-Yen Tu; Meng-Chih Lin; Ying-Huang Tsai; Meng-Jer Hsieh; Wen-Shuo Wu; Yuh-Min Chen
Journal:  Lung Cancer       Date:  2016-12-14       Impact factor: 5.705

2.  Optimizing RNA-Seq Mapping with STAR.

Authors:  Alexander Dobin; Thomas R Gingeras
Journal:  Methods Mol Biol       Date:  2016

3.  Incidence, risk factors, and dose-volume relationship of radiation-induced rib fracture after carbon ion radiotherapy for lung cancer.

Authors:  Takanori Abe; Katsuyuki Shirai; Jun-Ichi Saitoh; Takeshi Ebara; Hirofumi Shimada; Mutsumi Tashiro; Naoko Okano; Tatsuya Ohno; Takashi Nakano
Journal:  Acta Oncol       Date:  2015-09-23       Impact factor: 4.089

4.  CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization.

Authors:  J B Rattner; A Rao; M J Fritzler; D W Valencia; T J Yen
Journal:  Cell Motil Cytoskeleton       Date:  1993

5.  A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.

Authors:  D N Cagney; P G Thirion; M T Dunne; C Fleming; D Fitzpatrick; C M O'Shea; M A Finn; S O'Sullivan; C Booth; C D Collins; S J Buckney; A Shannon; J G Armstrong
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-10-31       Impact factor: 4.126

6.  Patterns of relapse in breast cancer: changes over time.

Authors:  Rinat Yerushalmi; Ryan Woods; Hagen Kennecke; Caroline Speers; Meg Knowling; Karen Gelmon
Journal:  Breast Cancer Res Treat       Date:  2009-08-22       Impact factor: 4.872

7.  Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Authors:  Chaolun An; Jiajun Zhang; Hongjun Chu; Chunyan Gu; Feng Xiao; Fengwei Zhu; Rujian Lu; Hai Shi; Hongfei Zhang; Xin Yi
Journal:  Pathol Oncol Res       Date:  2016-04-28       Impact factor: 3.201

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Authors:  James W Antoon; Elizabeth C Martin; Rongye Lai; Virgilo A Salvo; Yan Tang; Ashley M Nitzchke; Steven Elliott; Seung Yoon Nam; Wei Xiong; Lyndsay V Rhodes; Bridgette Collins-Burow; Odile David; Guandi Wang; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

10.  Treatment of Advanced Non-small-Cell Lung Cancer with Qi-Nourishing Essence-Replenishing Chinese Herbal Medicine Combined with Chemotherapy.

Authors:  Yabin Gong; Zhenye Xu; Changjuan Jin; Haibin Deng; Zhongqi Wang; Weidong Zhou; Ming Zhang; Xiaozhen Zhao; Lifang Wang
Journal:  Biol Proced Online       Date:  2018-04-01       Impact factor: 3.244

View more
  2 in total

1.  A Novel Prognostic Signature for Survival Prediction and Immune Implication Based on SARS-CoV-2-Related Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Yongbiao Huang; Sheng Chen; Lingyan Xiao; Wan Qin; Long Li; Yali Wang; Li Ma; Xianglin Yuan
Journal:  Front Bioeng Biotechnol       Date:  2022-01-24

2.  Bioinformatics Analysis of mRNAs and miRNAs for Identifying Potential Biomarkers in Lung Adenosquamous Carcinoma.

Authors:  Jin Nie; Ling Gong; Zhu Li; Dong Ou; Ling Zhang; Yi Liu; Jianyong Zhang; Daishun Liu
Journal:  Comput Math Methods Med       Date:  2022-03-02       Impact factor: 2.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.